Promising early-phase clinical trial data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Researchers are helping advance ovarian cancer care with breakthroughs that are reshaping treatment and early detection approaches.
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
This Trojan horse-like treatment strategy may help neutralize undruggable cancer drivers.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib...
On Monday, the U.S. Food and Drug Administration (FDA) announced the highly anticipated approval of the molecularly targeted therapeutic...
Last week saw a flurry of new anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) for...
Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults...
Last week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) for treating adults...